5/28/2023 0 Comments Tyme technologies stock forecast![]() ![]() It aimed at combatting the global crisis of multi-drug resistant (MDR). The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. Tyme Technologies Inc Stock - TYME Share Price Today, News and Discussion DIA 1. The company was formerly known as Global Group Enterprises Corp. ![]() The average price target is 0.00 with a high estimate of 0.00 and a low estimate of 0.00. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment NYU School of Medicine to examine multiple aspects of SM-88 mechanisms and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. Based on analysts offering 12 month price targets for TYME in the last 3 months. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. The company’s revenue is forecast to grow by 45. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2022 is 760k. Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
0 Comments
Leave a Reply. |